Buy ELDN by Sep 6, 2026.

Eledon Pharmaceuticals just announced the results of their study where 100% of patients achieved insulin independence (all 12 patients) that had type 1 diabetes. They have a market capitalization of $275 million so there is a ton of room to grow or even become an acquisition target by a larger company looking to replenish its revenues. Apparently there are over 2.1 million people with diagnosed type 1 diabetes in the US alone so this could be a massive opportunity. Seems …